INCRESYNC

This brand name is authorized in Austria, Estonia, Spain, Finland, Croatia, Ireland, Italy, Lithuania, Poland

Active ingredients

The drug INCRESYNC contains a combination of these active pharmaceutical ingredients (APIs):

1 Alogliptin
UNII JHC049LO86 - ALOGLIPTIN

Alogliptin is a potent and highly selective inhibitor of DPP-4, >10,000-fold more selective for DPP-4 than other related enzymes including DPP-8 and DPP-9. Alogliptin improves glycaemic control via a glucose-dependent mechanism, whereby insulin release is enhanced and glucagon levels are suppressed when glucose levels are high.

Read about Alogliptin
2 Pioglitazone
UNII X4OV71U42S - PIOGLITAZONE

Pioglitazone effects may be mediated by a reduction of insulin resistance. Pioglitazone appears to act via activation of specific nuclear receptors (peroxisome proliferator activated receptor gamma) leading to increased insulin sensitivity of liver, fat and skeletal muscle cells in animals. Treatment with pioglitazone has been shown to reduce hepatic glucose output and to increase peripheral glucose disposal in the case of insulin resistance.

Read about Pioglitazone

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
INCRESYNC Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
A10BD09 Pioglitazone and alogliptin A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BD Combinations of oral blood glucose lowering drugs
Discover more medicines within A10BD09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: EE Ravimiamet Identifier(s): 1626667, 1626678, 1626689, 1626690, 1626702, 1626713, 1626724, 1626735, 1626746, 1626757, 1626768, 1626779, 1626780, 1626791, 1626803, 1626814, 1626825, 1626836, 1626847, 1626858, 1626869, 1626870, 1626881, 1626892, 1626904, 1626915, 1626926, 1626937, 1626948, 1626959, 1626960, 1626971, 1626982, 1626993, 1627006, 1627017
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 113842003, 113842021
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 134709
Country: IT Agenzia del Farmaco Identifier(s): 043030016, 043030028, 043030030, 043030042, 043030055, 043030067, 043030079, 043030081, 043030093, 043030105, 043030117, 043030129, 043030131, 043030143, 043030156, 043030168, 043030170, 043030182, 043030194, 043030206, 043030218, 043030220, 043030232, 043030244, 043030257, 043030269, 043030271, 043030283, 043030295, 043030307, 043030319, 043030321, 043030333, 043030345, 043030358, 043030360
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1071372, 1071373, 1071374, 1071375, 1071376, 1071377, 1071378, 1071379, 1071380, 1071381, 1071382, 1071383, 1071384, 1071385, 1071386, 1071387, 1071388, 1071389, 1071390, 1071391, 1071392, 1071393, 1071394, 1071395, 1071396, 1071397, 1071398, 1071399, 1071400, 1071401, 1071402, 1071403, 1071404, 1071405, 1071406, 1071407
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100310938, 100310944, 100310950, 100310973

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.